MARKET

AEMD

AEMD

Aethlon Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.270
-0.180
-5.22%
Closed 19:43 09/20 EDT
OPEN
3.350
PREV CLOSE
3.450
HIGH
3.436
LOW
3.260
VOLUME
170.02K
TURNOVER
--
52 WEEK HIGH
12.49
52 WEEK LOW
1.290
MARKET CAP
50.31M
P/E (TTM)
-4.8989
1D
5D
1M
3M
1Y
5Y
How Good Are Aethlon Medical's Earnings? | Return On Capital Employed
According to data from Benzinga Pro, during Q1, Aethlon Medical's (NASDAQ:AEMD) reported sales totaled $131.97 thousand. Despite a 7.34% increase in earnings, the company posted a loss of $2.10 million.
Benzinga · 3d ago
Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Vir...
PR Newswire · 09/07 12:01
AEMD: Strong Cash Position to Advance the Hemopurifier; Clinical Trials Move Forward
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT 1Q FY 2022 Results
Benzinga · 08/16 16:10
SESN, BITF and ORGN among pre market gainers
Boxlight (NASDAQ:BOXL) +31% on Q2 earnings Pilgrim's Pride (NASDAQ:PPC) +20% after Brazil's JBS offers to purchase remainder of company Venus Concept (NASDAQ:VERO) +16% on Q2 earnings  CVD Equipment Corporation (NASDAQ:CVV) +14% on first production system ...
Seekingalpha · 08/13 12:31
Top Premarket Gainers
MT Newswires · 08/13 08:20
10 Penny Stocks Redditors are Buying in August
In this article, we discuss the 10 penny stocks Redditors are buying in August. If you want to skip our detailed analysis of these stocks, go directly to the 5 Penny Stocks Redditors are Buying in August. Retail investors, who use internet platforms like R...
Insider Monkey · 08/12 16:50
Aethlon Medical Q1 EPS $(0.16) Misses $(0.13) Estimate, Government Contract Revenue $132K
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 6.67 percent decrease over losses of $(0.15) per share from
Benzinga · 08/09 21:35
BRIEF-Aethlon Medical Announces First Quarter Financial Results And Provides Corporate Update
reuters.com · 08/09 20:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AEMD. Analyze the recent business situations of Aethlon Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AEMD stock price target is 9.33 with a high estimate of 11.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 966.62K
% Owned: 6.28%
Shares Outstanding: 15.39M
TypeInstitutionsShares
Increased
4
460.21K
New
8
74.46K
Decreased
5
11.34K
Sold Out
7
397.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.76%
Healthcare Equipment & Supplies
-1.59%
Key Executives
Chairman/Director
Edward Broenniman
Chief Executive Officer
Charles Fisher
Chief Financial Officer/Senior Vice President - Finance/Secretary/IR Contact Officer
James Frakes
Senior Vice President
Guy Cipriani
Other
Steven Larosa
Independent Director
Sabrina Johnson
Independent Director
Chetan Shah
No Data
About AEMD
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

Webull offers kinds of Aethlon Medical, Inc. stock information, including NASDAQ:AEMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEMD stock methods without spending real money on the virtual paper trading platform.